#1 Clinical Trials Search in Europe

Carbidopa

Carbidopa, a medication commonly used in combination with levodopa to treat Parkinson’s disease, is being investigated for its potential benefits in other medical conditions. This article examines several clinical trials exploring carbidopa’s effects on various disorders, including fibromyalgia, age-related macular degeneration, and familial dysautonomia. These studies aim to evaluate carbidopa’s safety, efficacy, and potential new applications in treating symptoms like pain, blood pressure variability, and vision problems.

Table of Contents

What is Carbidopa?

Carbidopa is a medication primarily used in the treatment of Parkinson’s disease. It is also known by several other names, including Lodosyn[1], DL-α-methyl-α-hydrazino-3,4-dihydroxyphenyl-propionic acid, HMD, and MK-486[2]. Carbidopa belongs to a class of drugs called decarboxylase inhibitors, which means it prevents the breakdown of certain chemicals in the body.

How Carbidopa Works

Carbidopa works by inhibiting an enzyme called aromatic L-amino acid decarboxylase (AAAD), also known as DOPA decarboxylase. This enzyme is responsible for converting levodopa (a medication used to treat Parkinson’s disease) into dopamine in the body. By inhibiting this enzyme, carbidopa helps to increase the amount of levodopa that reaches the brain[3].

One important characteristic of carbidopa is that it does not cross the blood-brain barrier at therapeutic doses. This means it primarily acts in the body’s periphery (outside the brain and spinal cord), allowing more levodopa to reach the brain where it’s needed[4].

Medical Conditions Treated with Carbidopa

Carbidopa is used to treat several medical conditions, including:

  • Parkinson’s Disease: This is the primary use of carbidopa. It’s often combined with levodopa to treat the symptoms of Parkinson’s disease, such as tremors, stiffness, and slow movement[5].
  • Familial Dysautonomia: This is a rare genetic disorder affecting the autonomic nervous system. Carbidopa is being studied for its potential to treat symptoms like nausea, vomiting, and blood pressure fluctuations in patients with this condition[1][2].
  • Fibromyalgia: Research is ongoing to determine if carbidopa, alone or in combination with other drugs, could help manage pain and other symptoms associated with fibromyalgia[4].

Combination Therapies

Carbidopa is often used in combination with other medications to enhance its effectiveness. Some common combinations include:

  • Carbidopa/Levodopa: This is the most common combination, used to treat Parkinson’s disease. Carbidopa allows more levodopa to reach the brain, enhancing its effectiveness[6].
  • Carbidopa/Levodopa/Entacapone: This triple combination is sometimes used in Parkinson’s disease patients who experience “wearing-off” symptoms between doses[5].
  • Carbidopa/Droxidopa: This combination is being studied for potential use in treating fibromyalgia[4].

Dosage and Administration

The dosage of carbidopa can vary depending on the condition being treated and whether it’s being used alone or in combination with other drugs. In clinical trials, doses have ranged from 75 mg to 600 mg per day, often divided into multiple doses throughout the day[2][3]. However, it’s crucial to follow your doctor’s instructions regarding dosage and administration.

Carbidopa is typically taken orally in tablet form. It may be taken with or without food, but consistency in how you take it is important[7].

Potential Side Effects

While carbidopa is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

  • Nausea
  • Dizziness
  • Headache
  • Changes in blood pressure

In studies of carbidopa for familial dysautonomia, researchers are particularly monitoring for any worsening of orthostatic hypotension (a sudden drop in blood pressure upon standing)[2].

Ongoing Research and Future Prospects

Researchers continue to explore new uses for carbidopa and ways to optimize its effectiveness. Some areas of ongoing research include:

  • Using carbidopa to treat excessive blood pressure variability in certain conditions[2].
  • Investigating the effects of different carbidopa/levodopa combinations on cognitive function and motor symptoms in Parkinson’s disease[7].
  • Exploring the potential of carbidopa in treating fibromyalgia symptoms[4].

These ongoing studies may lead to new applications for carbidopa or improved treatment regimens for existing conditions in the future.

Condition Study Design Intervention Primary Outcome Measures
Parkinson’s Disease Randomized, double-blind, crossover High-dose (450mg) vs. low-dose (75mg) carbidopa Motor response to levodopa infusion, tapping speed
Fibromyalgia Randomized, double-blind, placebo-controlled Droxidopa alone and with carbidopa (25mg or 50mg) Pain reduction, quality of life measures
Age-related Macular Degeneration Randomized, placebo-controlled Carbidopa-levodopa (25-100mg) at varying doses Progression of geographic atrophy area
Familial Dysautonomia Randomized, double-blind, crossover High-dose (600mg) vs. low-dose (300mg) carbidopa Blood pressure variability, adverse events

FAQ

  • What is carbidopa and how does it work? Carbidopa is a medication that inhibits the enzyme aromatic L-amino acid decarboxylase (AAAD). It is typically used with levodopa to treat Parkinson's disease. Carbidopa prevents the breakdown of levodopa in the bloodstream, allowing more of it to reach the brain where it can be converted to dopamine.
  • What conditions are being studied for potential carbidopa treatment? Clinical trials are exploring carbidopa's potential in treating conditions such as fibromyalgia, age-related macular degeneration, familial dysautonomia, and nausea and vomiting in various disorders. These studies aim to evaluate its effects on pain, blood pressure variability, vision problems, and other symptoms.
  • How is carbidopa being studied in fibromyalgia patients? A clinical trial is investigating the use of carbidopa alone and in combination with droxidopa for treating pain associated with fibromyalgia. The study aims to determine the optimal dosage and evaluate the effects on pain reduction, fatigue, sleep disorders, and overall quality of life in fibromyalgia patients.
  • What is the potential benefit of carbidopa in age-related macular degeneration? A study is examining whether carbidopa-levodopa treatment can slow the progression of geographic atrophy in dry age-related macular degeneration. The research is based on the hypothesis that levodopa may stimulate the release of protective factors in the retina, potentially delaying the onset or progression of AMD.
  • How is carbidopa being studied in familial dysautonomia? A clinical trial is evaluating carbidopa's potential to reduce excessive blood pressure variability and inhibit catecholamine-induced paroxysmal hypertension in patients with familial dysautonomia. The study compares high-dose and low-dose carbidopa treatments to assess safety, tolerability, and effectiveness in managing blood pressure fluctuations.

Ongoing Clinical Trials on Carbidopa

  • An observational study of carbidopa and levodopa use with a new dispensing device and app in patients with Parkinson’s disease

    Recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study of levodopa and carbidopa treatment for patients with neurodevelopmental disorder caused by CTNNB1 gene mutation

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Long-term safety and effectiveness follow-up study of AB-1005 gene therapy in patients with Parkinson’s disease or multiple system atrophy

    Not yet recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Comparative Bioavailability of Inhaled Levodopa (Levodopa Cyclops) versus Inhaled Levodopa Powder with Carbidopa in Healthy Adults for Parkinson’s Disease

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria

  • Study on the Effectiveness and Safety of ND0612 Infusion vs. Oral Treatment for Parkinson’s Disease Patients with Motor Fluctuations

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Italy Poland +3

  • Study on the Long-Term Safety of ND0612 (Carbidopa, Levodopa) Infusion for Patients with Advanced Parkinson’s Disease

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Austria France Italy Poland

Glossary

  • Aromatic L-amino acid decarboxylase (AAAD): An enzyme that converts levodopa to dopamine. Carbidopa inhibits this enzyme outside the brain, allowing more levodopa to reach the central nervous system.
  • Bradykinesia: Slowness of movement, a common symptom in Parkinson's disease that is often measured in clinical trials using tasks like finger tapping.
  • Dyskinesia: Abnormal, uncontrolled, involuntary movements that can occur as a side effect of long-term levodopa treatment in Parkinson's disease.
  • Entacapone: A medication often used in combination with carbidopa and levodopa to treat Parkinson's disease. It helps prolong the effects of levodopa by inhibiting its breakdown.
  • Familial dysautonomia: A rare genetic disorder affecting the autonomic nervous system, characterized by problems with regulating blood pressure, body temperature, and other autonomic functions.
  • Geographic atrophy: An advanced form of dry age-related macular degeneration characterized by the death of retinal pigment epithelium cells and overlying photoreceptors in the macula.
  • Levodopa: A medication used to treat Parkinson's disease by increasing dopamine levels in the brain. It is usually combined with carbidopa to enhance its effectiveness.
  • Norepinephrine: A neurotransmitter and hormone that plays a role in the body's fight-or-flight response and is involved in regulating blood pressure and other autonomic functions.
  • Parkinson's disease: A progressive neurological disorder characterized by tremor, stiffness, and difficulty with movement, balance, and coordination.
  • Wearing-off: A complication of long-term levodopa therapy in Parkinson's disease where the medication's effects wear off before the next dose, leading to a return of symptoms.

References

  1. https://clinicaltrials.gov/study/NCT01212484
  2. https://clinicaltrials.gov/study/NCT02553265
  3. https://clinicaltrials.gov/study/NCT01399905
  4. https://clinicaltrials.gov/study/NCT01323374
  5. https://clinicaltrials.gov/study/NCT00391898
  6. https://clinicaltrials.gov/study/NCT00601978
  7. https://clinicaltrials.gov/study/NCT04325503